178 related articles for article (PubMed ID: 26863637)
61. RIZ1: a potential tumor suppressor in glioma.
Zhang C; Zhu Q; He H; Jiang L; Qiang Q; Hu L; Hu G; Jiang Y; Ding X; Lu Y
BMC Cancer; 2015 Dec; 15():990. PubMed ID: 26690953
[TBL] [Abstract][Full Text] [Related]
62. Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo.
Jaraíz-Rodríguez M; Talaverón R; García-Vicente L; Pelaz SG; Domínguez-Prieto M; Álvarez-Vázquez A; Flores-Hernández R; Sin WC; Bechberger J; Medina JM; Naus CC; Tabernero A
Neuro Oncol; 2020 Apr; 22(4):493-504. PubMed ID: 31883012
[TBL] [Abstract][Full Text] [Related]
63. Cyclosporine a induces growth arrest or programmed cell death of human glioma cells.
Zupanska A; Dziembowska M; Ellert-Miklaszewska A; Gaweda-Walerych K; Kaminska B
Neurochem Int; 2005 Nov; 47(6):430-41. PubMed ID: 16087277
[TBL] [Abstract][Full Text] [Related]
64. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
65. Identification and characterization of the promoter of human ATF5 gene.
Wei Y; Ge Y; Zhou F; Chen H; Cui C; Liu D; Yang Z; Wu G; Gu J; Jiang J
J Biochem; 2010 Aug; 148(2):171-8. PubMed ID: 20423929
[TBL] [Abstract][Full Text] [Related]
66. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
67. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
68. The transcription factor ATF5: role in neurodevelopment and neural tumors.
Greene LA; Lee HY; Angelastro JM
J Neurochem; 2009 Jan; 108(1):11-22. PubMed ID: 19046351
[TBL] [Abstract][Full Text] [Related]
69. Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma.
Huang R; Qian D; Hu M; Zhang X; Song J; Li L; Chen H; Wang B
Oncol Lett; 2015 Nov; 10(5):2812-2820. PubMed ID: 26722247
[TBL] [Abstract][Full Text] [Related]
70. High-yield expression in E. coli and refolding of the bZIP domain of activating transcription factor 5.
Ciaccio NA; Moreno ML; Bauer RL; Laurence JS
Protein Expr Purif; 2008 Dec; 62(2):235-43. PubMed ID: 18718539
[TBL] [Abstract][Full Text] [Related]
71. Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients.
Feldheim J; Kessler AF; Schmitt D; Wilczek L; Linsenmann T; Dahlmann M; Monoranu CM; Ernestus RI; Hagemann C; Löhr M
Onco Targets Ther; 2018; 11():8673-8684. PubMed ID: 30584325
[TBL] [Abstract][Full Text] [Related]
72. ATF5: development of oncogenic resistance to radiotherapy.
Ishihara S; Haga H
Aging (Albany NY); 2015 Jul; 7(7):453-4. PubMed ID: 26187904
[No Abstract] [Full Text] [Related]
73. Comprehensive Behavioral Analysis of Activating Transcription Factor 5-Deficient Mice.
Umemura M; Ogura T; Matsuzaki A; Nakano H; Takao K; Miyakawa T; Takahashi Y
Front Behav Neurosci; 2017; 11():125. PubMed ID: 28744205
[TBL] [Abstract][Full Text] [Related]
74. Overexpression of activating transcription factor 5 in human rectal cancer.
Kong X; Meng W; Zhou Z; Li Y; Zhou B; Wang R; Zhan L
Exp Ther Med; 2011 Sep; 2(5):827-831. PubMed ID: 22977583
[TBL] [Abstract][Full Text] [Related]
75. Analysis of electroencephalographic findings in 40 cases of verified brain tumor; electroencephalographic findings in malignant cerebral gliomas.
CUNEO HM; RAND CW; SJAARDEMA H
Bull Los Angel Neuro Soc; 1949 Jun; 14(2):86-103. PubMed ID: 18152787
[No Abstract] [Full Text] [Related]
76. Transdifferentiation Induced Neural Stem Cells for the Treatment of Malignant Gliomas.
Chakraborty S; Schneider J; Boockvar JA
Neurosurgery; 2016 Aug; 79(2):N17-8. PubMed ID: 27428639
[No Abstract] [Full Text] [Related]
77. Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents.
Zhou Q; Sun X; Pasquier N; Jefferson P; Nguyen TTT; Siegelin MD; Angelastro JM; Greene LA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065488
[TBL] [Abstract][Full Text] [Related]
78. Massive spontaneous hemorrhage in gliomas; a report of seven verified cases.
MANGANIELLO LO
J Nerv Ment Dis; 1949 Oct; 110(4):277-98. PubMed ID: 15392373
[No Abstract] [Full Text] [Related]
79. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
80. The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer.
Sears TK; Angelastro JM
Oncotarget; 2017 Oct; 8(48):84595-84609. PubMed ID: 29137451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
